|
Median age at diagnosis, year (range, IQR)
|
73 (30-98, 58-80)
| |
|
Gender
| | |
|
Male
|
128
|
71.5
|
|
Female
|
51
|
28.5
|
|
Histology
| | |
|
Carcinoma, unclassifiable
|
83
|
46.4
|
|
Adenocarcinoma
|
71
|
39.7
|
|
Squamous cell carcinoma
|
6
|
3.4
|
|
Neuroendocrine carcinoma
|
12
|
6.7
|
|
Others
|
7
|
3.9
|
|
Histologic grade
| | |
|
Poorly differentiated or Undifferentiated
|
31
|
17.3
|
|
Unspecified
|
148
|
82.7
|
|
Performance status
| | |
|
0
|
19
|
10.6
|
|
1
|
67
|
37.4
|
|
2
|
44
|
24.6
|
|
3
|
27
|
15.1
|
|
4
|
22
|
12.3
|
|
Initial site at diagnosis
| | |
|
Liver
|
38
|
21.2
|
|
Lung
|
23
|
12.8
|
|
Bone
|
47
|
26.3
|
|
Central nervous system
|
7
|
3.9
|
|
Peritoneum
|
18
|
10.1
|
|
Lymph nodes
|
43
|
24
|
|
Others
|
3
|
1.7
|
|
Sites of disease involvement
| | |
|
Liver
|
80
|
44.7
|
|
Lung and pleural
|
87
|
48.6
|
|
Bone
|
74
|
41.3
|
|
Central nervous system
|
14
|
7.8
|
|
Lymph nodes
|
107
|
59.8
|
|
No. of metastatic organs
| | |
|
1
|
40
|
22.3
|
|
2
|
52
|
29.1
|
|
> 2
|
87
|
48.6
|
|
Treatment
| | |
|
Chemotherapy
|
118
|
66.0
|
|
Radiotherapy
|
52
|
29.1
|
|
Tyrosine kinase inhibitors
|
2
|
1.1
|
|
Chemotherapy regimens
| | |
|
Cisplatin-based
|
89
|
75.4
|
|
5-FU-based
|
51
|
43.2
|
|
Etoposide-based
|
45
|
38.1
|
|
Gemcitabine-based
|
17
|
14.4
|
|
Taxane-based
|
13
|
11.0
|
|
Oxaliplatin-based
|
11
|
9.3
|
